slides · global inventory
Compare Peers
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 9,820
Current window 7,171-7,200
Pages 328
Rows per page 30
Slide function
7,171-7,200 of 9,820
09
The slide uses a list-based comparison and a logo-grid to frame the competitive landscape.Genelux | Investor Presentation Deck | 38 slides · Genelux
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
05
The slide uses a 2D matrix/positioning map to illustrate market positioning based on ECG technology lead count vs. clinical diagnostic capabilities.HeartBeam | Investor Presentation Deck | 18 slides · HeartBeam
Pitch deck Investor relations Beat · Agitate1 hit
09
The slide uses three side-by-side bar charts to demonstrate dominance in specific financial advisory niches.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
10
The slide uses a series of bar charts to demonstrate market leadership across multiple verticals.Houlihan Lokey | Investor Presentation Deck | 33 slides · Houlihan Lokey
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
06
The slide uses a bar chart combined with a data table to highlight safety advantages. It includes a disclaimer about cross-trial comparisons.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
10
The slide uses a comparative timeline visualization to highlight the superior safety and efficacy profile of NXC-201.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & ContextLoop · Golden Circle1 hit
13
The slide uses a dual-metric comparison (Hematologic Response vs. Cardiac Response) to highlight NXC-201's efficacy.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
14
The slide uses a table structure to contrast treatment efficacy and patient outcomes, with a bar chart at the bottom illustrating patient population growth.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Hypothesis Test1 hit
17
Includes detailed clinical trial references in the footer.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · VisualizationLoop · Why Now1 hit
24
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
25
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
26
The slide uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Desire1 hit
30
The slide highlights specific safety metrics (CRS and ICANS) for two dosage groups (100x10^6 and 300x10^6 cells).Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
54
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
57
The slide compares efficacy benchmarks of established competitors (AbbVie, J&J, Takeda) to set a baseline for the IMX-120 opportunity.Immix Biopharma | Investor Presentation Deck | 57 slides · Immix Biopharma
Pitch deck Investor relations Beat · Satisfaction1 hit
30
The slide uses two bar charts to illustrate growth metrics, highlighting Jefferies' outperformance relative to peers.Jefferies Financial Group | Investor Presentation Deck | 74 slides · Jefferies
Conference presentation Investor relations 1 hit
40
The slide uses arrows to indicate ranking changes and highlights Jefferies' row in light blue.Jefferies Financial Group | Investor Presentation Deck | 74 slides · Jefferies
Conference presentation Investor relations 1 hit
47
The chart highlights Jefferies' performance relative to competitors, emphasizing a positive 38.1% growth compared to mostly negative or lower growth among peers.Jefferies Financial Group | Investor Presentation Deck | 74 slides · Jefferies
Conference presentation Investor relations 1 hit
11
jetBlue | Results Presentation Deck | 20 slidesjetBlue | Results Presentation Deck | 20 slides · jetBlue
Conference presentation Investor relations Beat · Satisfaction1 hit
14
The table compares Cyramza+Docetaxel, Docetaxel alone, and THIO+Libtayo.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
16
DCR stands for Disease Control Rate. The table compares historical clinical trial data (KEYNOTE 024, REVEL, RWD) against the company's own THIO-101 trial data.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
25
The table compares three treatment regimens across four categories: Expected Efficacy, Safety Profile, Administration, and Trial of Reference.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
26
The table compares historical standard of care data against planned THIO-102 trial outcomes.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
27
MAIA Biotechnology | Investor Presentation Deck | 39 slidesMAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
37
The slide uses a logo-grid and metric-grid to establish valuation context.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
04
The slide uses hub-and-spoke diagrams to visually contrast decentralized vs centralized networks.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
18
The slide uses two scatter plots to compare sensitivity vs specificity for CRC and AA, with Mainz Biomed highlighted as a top performer.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
04
The slide uses hub-and-spoke diagrams to visually contrast decentralized vs centralized networks.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
19
The slide uses two scatter plots to compare diagnostic performance metrics against competitors like Guardant Health, Cologuard, and CellMax Life.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Market SizeLoop · Mece Breakdown1 hit